promotes prostate cancer metastasis, but the precise molecular mechanisms by which it achieves this are unknown. Here, by integrating Argonaute high-throughput sequencing of RNA isolated by crosslinking immunoprecipitation (Ago-HITS-CLIP) with RNA sequencing and exon-intron split analysis, we defined a 163-gene miR-194 "targetome" in prostate cancer. These target genes were predominantly down-regulated through canonical 3'UTR recognition sites and were enriched within pathways involved in cytoskeletal organisation and cell movement. In clinical prostate cancer samples, miR-194 activity was inversely correlated with the androgen receptor (AR) signalling axis. At a mechanistic level, this inverse correlation was explained by down-regulation of miR-194 expression by AR. Accordingly, miR-194 expression and activity was significantly elevated in neuroendocrine prostate cancer (NEPC), an aggressive AR-independent disease subtype. enhanced the transdifferentiation of prostate adenocarcinoma cells to a neuroendocrine-like state, at least in part by targeting FOXA1, a transcription factor with a key role in maintaining the prostate epithelial lineage. Importantly, a miR-194 inhibitor effectively inhibited the growth of cell lines and patient-derived organoids with neuroendocrine features. Overall, our study reveals a novel posttranscriptional mechanism regulating the plasticity of prostate cancer cells and provides a rationale for targeting miR-194 in this NEPC.
INTRODUCTION
Cellular plasticity, also referred to as lineage plasticity or lineage switching, is a process whereby cells exhibit reversible changes in properties and phenotypes. Cancer cells exploit this phenomenon in response to a targeted therapy, acquiring the phenotypic characteristics of another lineage that does not depend on the drug target for survival (1) . This phenomenon allows cancer cells to adapt to new or stressful conditions and is increasingly recognised as a key feature of cancer progression (2) .
As first-line treatment for metastatic prostate cancer (PCa), androgen deprivation therapy targets the exquisite dependence of tumours on the androgen receptor (AR) for their growth. While initially effective, patients inevitably develop resistance and progress to castration-resistant prostate cancer (CRPC). Most CRPC tumours exhibit adaptive changes that maintain AR activity despite the low androgen environment, an understanding that led to the development of highly potent secondgeneration AR-targeted therapies (e.g. Enzalutamide and Abiraterone). However, response to these newer agents is also limited in most cases (3) . It has become increasingly clear that prolonged targeting of the AR, particularly with the more potent second-generation therapies, can drive cellular plasticity in CRPC. This plasticity is characterised by cells losing dependence on AR and gaining new phenotypes (i.e. aggressive variant PCa), with the most well recognised of these being a neuroendocrine (NE)-like state that is characterised by the expression of neuroendocrine, neuronal, developmental and stem cell markers (1) . Neuroendocrine prostate cancer (NEPC) is evident in ~15-25% of CRPC tumours (4, 5) and exhibits aggressive clinical features; indeed, patients with NEPC have a median overall survival time of <1 year (4) . A deeper understanding of how AR-targeted therapies promote lineage plasticity and the emergence of aggressive disease phenotypes such as NEPC is essential to improve patient outcomes.
Genomic comparisons of NEPC and CRPC adenocarcinoma (CRPC-Adeno) have revealed surprisingly few genetic differences between these disease subtypes; reproducible alterations in NEPC include higher incidences of RB1 and TP53 loss and more frequent amplification of MYCN and AURKA (6, 7) . The similarities in mutational landscapes between NEPC and CRPC-Adeno suggest that the plasticity underlying transdifferentiation from adenocarcinoma to an NE-like state is predominantly mediated by changes in epigenetics, transcriptional programs and protein function in the tumour cells, as opposed to selection and outgrowth of rare genetic variants (1) .
In this study, we identified miR-194 as a novel post-transcriptional regulator of transdifferentiation in PCa. By targeting genes that suppress plasticity, such as FOXA1, miR-194 drives the emergence and growth of NEPC, a finding that justifies further investigation of miRNAbased therapies for this aggressive CRPC subtype.
MATERIAL AND METHODS

Cell lines and cell culture
LNCaP, PC3 and 22RV1 cell lines were purchased from the American Type Culture Collection (ATCC). LNCaP-MR42D and LNCaP-MR49F cell lines have been described previously (8) . LNCaP and 22RV1 cell lines were maintained in RPMI-1640 (Sigma) containing 10% Fetal Bovine Serum (FBS) (Sigma). PC3 cell lines were maintained in RPMI-1640 containing 5% FBS. LNCaP-MR42D
and LNCaP-MR49F cells were maintained in RPMI-1640 containing 10% FBS and 10μM
Enzalutamide. For serum starvation experiments, cells were grown in phenol red-free RPMI-1640 containing 10% dextran-coated charcoal (DCC) stripped serum. Cell lines were subjected to regular mycoplasma testing. All cell lines underwent verification by short tandem repeat profiling by CellBank Australia.
Cell line transfections
Transient transfection of cell lines were performed using RNAiMAX Transfection Reagent (Life Technologies) according to the manufacturer's instructions. For HITS-CLIP and RNA-seq experiments, 22RV1 cells were transfected with 20nM miRVana mimic (miR-194 or negative control; Ambion). For all other experiments, cells were transfected with 20nM miRNA mimics from Shanghai GenePharma.
For miR-194 inhibition, cells were transfected with 12.5 or 6.25nM locked nucleic acid (LNA) miRNA inhibitors (miR-194 LNA inhibitor or negative control inhibitor; Qiagen).
Argonaute
high-throughput sequencing of RNA isolated by crosslinking
immunoprecipitation (Ago-HITS-CLIP)
The Ago-HITS-CLIP method was adapted from published methods (9,10), incorporating modifications from eCLIP (11, 12) . 22RV1 cells were seeded in 10 cm cell culture dishes and transfected in suspension with 20 nM miRVana mimic (miR-194 were excised from the nitrocellulose. RNA was extracted by proteinase K digestion (2 mg/mL proteinase K, 100 mM Tris-HCl pH 7.5, 50 mM NaCl, 10 mM EDTA, 0.2% SDS) at 50°C for 60 min on a Thermomixer (1200 rpm) followed by extraction with acid phenol (ThermoFisher, AM9712) and precipitation with 1:1 isopropanol:ethanol. RNA was pelleted by centrifugation then separated on a 15% denaturing polyacrylamide gel (1:19 acrylamide, 1 X TBE, 7 M urea). The wet gel was wrapped in plastic wrap and exposed to a phosphor screen and imaged using a Typhoon. Gel slices were cut corresponding to the expected size of the cross-linked RNA eluted by the "crush and soak" method as previously described (10) .
Reverse transcription, 5' linker ligation and amplification were performed essentially as previously described (11) using SR-RT primer for reverse transcription (IDT, AGACGTGTGCTCTTCCGATCT) with SuperScript IV, and a custom synthesised 5' linker (IDT, 5'SRdeg /5Phos/NN NNN NNN NNG ATC GTC GGA CTG TAG AAC TCT GAA C/3SpC3/). Products were amplified for 20 cycles using a common forward primer (NEBNext SR primer for Illumina) and barcoded reverse primers for each sample (NEBNext Index primers for Illumina). PCR products were purified using Qiagen Qiaquick PCR purification kit, separated on an 8% acrylamide (29:1) TBE nondenaturing gel, stained with SYBR Gold nucleic acid gel stain (ThermoFisher) and imaged on a ChemiDoc (BioRad). Products corresponding to an insert size of ~30 -70 nt were excised from the gel and extracted by the "crush and soak" method as previously described (10) . Library quality and quantity was assessed by Bioanalyzer (Agilent) and qPCR, pooled and sequenced on an Illumina -slocal 0, --llocal 0, --fe-cutoff 10, -q 0.05). Peak calling was performed using pooled alignment files and carried out separately for each strand. The resulting peak files from each strand were merged.
Features in the vicinity of peak loci and enrichment of motifs within peaks were determined and analysed using Homer (18) . Alignments were visualised and interrogated using IGV (19) .
CLIP using a control antibody was performed on a single biological replicate of control transfected cells but yielded very little sequence data and was excluded from the analysis. 3), following protocols as described (22) . Graphical representations of differentially expressed genes were generated using Glimma (23) .
Alignments were visualised and interrogated using the Integrative Genomics Viewer v2.3.80 (19) .
Exon Intron Split analysis (EISA) was performed as described previously (24) . To refine the miR-194 targetome, only post-transcriptionally downregulated genes (i.e. genes with log2FC(dExon-dIntron) < 0) and a FDR cutoff of 0.05) were considered as targets.
Gene set enrichment analysis
Genes were ranked according to expression using the Signal2Noise metric. Gene Set Enrichment Analysis (Preranked analysis) (25) was implemented using the Broad Institute's public GenePattern server with default parameters.
Analysis of miR-194 activity in published datasets single sample GSEA (ssGSEA)
Expression data was downloaded from GEO (Kumar 2016 (GSE77930) (26)), cBioportal (MSKCC (27) and SU2C (28)), TCGA (29) and dbGAP (Beltran 2016 (30) ). ssGSEA (31) was implemented using the Broad Institute's public GenePattern server, using rank normalisation and default parameters.
Since miRNAs repress expression of their target genes, miR-194 activity was calculated as the inverse value of ssGSEA scores for the miR-194 targetome.
RNA extractions from cell lines and patient-derived xenograft (PDX) tissues
Total RNA from cell lines was extracted using TRI Reagent (Sigma), as described previously (32) .
PDX tissues preserved in RNALater were provided by the Melbourne Urology Research Alliance (MURAL) (33) . Tissues were homogenised in Qiazol (Qiagen) with a Precellys24 Tissue Homogeniser (Bertin Technologies) and total RNA was extracted using a miRNeasy Mini Kit (Qiagen), according to the manufacturer's instructions.
Quantitative RT-PCR (qRT-PCR) analysis of mRNA
Total RNA was treated with Turbo DNA-free kit (Invitrogen), and reverse transcribed using iScript Reverse Transcriptase Supermix kit (Bio-Rad). qRT-PCR was performed in triplicate as described previously (34) . GAPDH levels were used for normalization of qRT-PCR data. Primer sequences are available on request.
qRT-PCR analysis of miR-194
Total RNA (100 ng) was reverse transcribed using the TaqMan MicroRNA Reverse Transcription Kit 
Proliferation and cell viability assays
Proliferation curves for cell lines treated with LNA miRNA inhibitors were performed using the Trypan blue exclusion assay. Cells were seeded at 1×10 4 (PC3) or 4.5×10 4 (LNCaP-MR42D, LNCaP-MR49F, LNCaP) in 12-well plates and transfected in suspension with 12.5 or 6.25 nM miR LNA inhibitor using RNAiMAX (Life Technologies). Live and dead cells were quantified at indicated time points using
Trypan blue.
For cell viability assays, LNCaP-MR42D or LNCaP cells were seeded at 4×10 3 cells/well in 96-well plates and transfected in suspension with 12.5 or 6.25nM miR LNA inhibitor using RNAiMAX (Life Technologies). Cell viability was assesses using the Cell Titer-Glo Luminescent Cell Viability Assay (Promega) according to manufacturer's recommendations.
Neurite length measurement
Length of neurite extensions were measured using the Simple Neurite Tracer plugin (35) for Fiji/ImageJ . Neurite lengths were measured from ≥ 3 images per replicate. Representative images with overlaid traces were generated using the NeuronJ plugin (36) for Fiji/ImageJ
Western blots
Protein extraction from cells using RIPA buffer and western blotting was done as described in (34) .
Primary antibodies used in western blotting were FOXA1 (Abcam, Ab23738) and GAPDH (Millipore, MAB374). Immunoreactive bands were visualised using Clarity Western ECL Substrate (Bio-Rad).
Organoid culture and transfections
PDXs were established by the Melbourne Urology Research Alliance (MURAL) (Monash University Human Research Ethics Committee approval 12287). The established PDXs were grown as subcutaneous grafts in male NSG mice supplemented with testosterone implants according to animal ethics approval (17963), as previously described (33, 37) . PDXs were routinely authenticated using short tandem repeat profiling (GenePrint 10, Promega) at the Australian Genome Research Facility. Supplementary Table S1 .
Organoids were transfected with miR LNA inhibitors essentially as described previously (39) .
Briefly, organoid were collected and 50,000 cells were resuspended in 450µl of organoid culture media and 50μl of transfection mix containing RNAiMAX with 25, 100, and 250 nM miR-194 or NC LNA inhibitor. Cells were centrifuged in a pre-warmed centrifuge at 32°C, 600g for 1h. After centrifuging, cells were incubated in a tissue culture incubator at 37°C for 2-4h and then collected in 1.5ml centrifuge tubes by centrifugation at 300 g for 5 min at room temperature. Cell pellets were resuspended in 50 ul Matrigel and seeded out in 10 μl matrigel discs in 96-well plates. Plates were inverted and incubated at 37°C for 15 minutes to allow Matrigel to solidify, then overlaid with 100mL of organoid culture medium. Organoid forming efficiency was determined at 7 days post-transfection as described previously (33) . Organoid viability was assessed at 7 days post-transfection using the CellTiter-Glo® Luminescent Cell Viability Assay kit (Promega), as per the manufacturer's instructions.
Statistical Analysis
Statistical analysis for grouped quantitative data were carried out using two-tailed unpaired t-test or ANOVA (GraphPad Prism 7) . The relationships between activity scores were determined using Pearson's correlation coefficient (Graphpad Prism 7).
RESULTS
Global identification of transcripts targeted by miR-194 in prostate cancer
Our earlier work demonstrated that miR-194 can promote epithelial-mesenchymal transition (EMT) and metastasis, at least in part by targeting the tumour suppressor SOCS2 (32) . However, miRNAs target tens to hundreds of genes, so we hypothesised that elucidating additional miR-194 targets Supplementary Table S2 ). An example peak at the ZBTB10 gene is shown in Figure 1A . Highlighting the robustness of the data, the vast majority (94%) of peaks were within genes, most commonly in exons, 3'UTRs and introns ( Figure   1B ). Furthermore, unbiased de novo motif analysis revealed that the most strongly enriched sequence within the peaks was a seed recognition site for miR-194 ( Supplementary Table S3 ), which was concentrated within the centres of peaks ( Figure 1C ).
MiRNAs typically reduce the levels of their target mRNAs (40) . Therefore, we conducted RNA-seq of cells transfected with miR-194 mimic or a control. MiR-194 elicited significant changes to the transcriptome, causing down-regulation of 2,626 and up-regulation of 2,485 transcripts ( Figure   1D ). We identified a strong bias toward down-regulation of mRNAs with miR-194 Ago-HITS-CLIP peaks in 3'UTRs, whereas mRNAs with peaks in coding regions were less strongly biased toward down-regulation and those with peaks in introns were collectively unchanged ( Figure 1E ;
Supplementary Figure S1A ). This is consistent with previous studies demonstrating that 3'UTRs are the key sequences through which miRNAs exert their activity (40) . Similarly, transcripts with 3'UTR peaks containing miR-194 seed recognition sequences tended to be more robustly down-regulated than those lacking such sequences ( Figure 1F; Supplementary Figure S1B ).
To further prioritise putative miR-194 target genes, we utilised Exon-Intron Split Analysis, a bioinformatic technique that separates transcriptional and post-transcriptional effects by evaluating whether RNA-seq reads map to exons or introns (41) . The quality and number of predicted 3'UTR miR-194 target sites was strongly associated with genes down-regulated at a post-transcriptional but not a transcriptional level (Supplementary Figure S1C) , indicating that EISA can differentiate between direct miR-194 targets and downstream changes to the transcriptome. Moreover, transcripts exhibiting post-transcriptional but not transcriptional alterations exhibited stronger down-regulation by miR-194 compared to all transcripts containing Ago-HITS-CLIP peaks ( Figure 1G ).
With these observations in mind, we applied a filtering strategy whereby transcripts with 3'UTR Ago-HITS-CLIP peaks containing seed recognition sequences and predicted to be downregulated post-transcriptionally were included in a final 163-gene miR-194 "targetome". To assess the biological relevance of the "targetome", its correlation with miR-194 levels was evaluated in 65 primary tumours and 7 metastases (42) . We observed a distinct bias toward inverse correlation between miR-194 and its target genes ( Figure 1H ), supporting the notion that our experimental strategy integrating biochemistry, molecular biology and bioinformatics (i.e. Ago-HITS-CLIP, RNA-seq and EISA) identified bona fide targets.
miR-194 expression and activity is negatively correlated with AR signalling
Gene ontology analysis of the miR-194 targetome revealed enrichment for genes associated with cytoskeletal remodelling, cell adhesion and cell motility ( Supplementary Table S4 ), which likely relates to the ability of miR-194 to enhance prostate cancer cell migration and invasion and elicit an EMT (32) .
To more specifically evaluate the targetome in clinical prostate cancer, we used single sample gene set enrichment analysis (ssGSEA) of our high-confidence targetome to generate miR-194 activity scores in clinical cohorts, which were then compared to equivalent scores generated from the same cohorts for the "Hallmark" biological gene sets (43) . Amongst other robust associations, one striking finding was that miR-194 activity was strongly inversely correlated with AR signalling across all cohorts examined (Figure 2A ; Supplementary Table S5 ). This observation was validated using a more refined set of AR target genes ( Figure 2B ) recently generated by Sowalsky and colleagues (44) .
The strength of this negative association led us to examine whether the miR-194 targetome was enriched for AR target genes, but there was only a limited overlap between these gene sets ( Figure 2C ). Moreover, our Ago-HITS-CLIP and transcriptomic data indicated that miR-194 does not target the AR transcript (Supplementary Figure S2 ). An alternative (and/or additional) explanation for this inverse relationship could be that AR regulates the expression of miR-194. Indeed, levels of miR-194 in the androgen-sensitive LNCaP model were decreased by the potent androgen DHT but increased by the AR antagonist Enzalutamide ( Figure 2D ). In accordance with these findings, extended culture of cells in androgen-depleted conditions led to upregulation of miR-194 ( Figure 2E ).
Collectively, these data reveal that AR represses expression of miR-194, which (at least partly) explains the negative association between these factors in clinical prostate cancer.
miR-194 activity and expression is elevated in neuroendocrine prostate cancer
NEPC is associated with loss of canonical AR activity (1) . Given the inverse relationship between miR-194 and AR, we therefore hypothesised that its activity would be elevated in clinical NEPC.
Indeed, miR-194 activity (estimated by ssGSEA) was significantly higher in NEPC compared to CRPC-Adeno tumours in multiple distinct cohorts ( Figure 3A and Supplementary Figure S3 ).
Moreover, miR-194 activity was correlated with established NEPC gene sets ( Figure 3B ).
We next examined whether miR-194 itself was over-expressed in NEPC. In the absence of miRNA expression data from clinical samples, we turned to a panel of 13 patient-derived xenografts (PDXs) established through the Melbourne Urological Research Alliance (MURAL), 6 of which have features of NEPC (33) . Importantly, miR-194 expression was higher in the NEPC versus AR-positive adenocarcinoma PDXs ( Figure 3C ), further demonstrating its association with this disease subtype.
Loss of AR expression and/or activity during the transition to NEPC likely explains -at least
partly -increased miR-194 expression in this disease state. However, since we have also noted elevated miR-194 expression and activity in metastases and "poor outcome" primary tumours (45) Figure 3D ). Importantly, gain/amplification of these loci were associated with elevated miR-194 levels ( Figure 3E ). These data suggest that copy number gain can result in increased miR-194 expression in aggressive prostate tumours and NEPC.
miR-194 promotes the emergence of a neuroendocrine features in prostate cancer
To determine whether miR-194 can directly influence the emergence of a NE-like state, we examined the response of adenocarcinoma PCa cells to transfection with a miR-194 mimic. Exogenous miR-194 led to upregulation of NE marker genes ( Figure 4A ) and increased neurite length in LNCaP cells ( Figure 4B ), an effect that was recapitulated in the 22Rv1 cell line model ( Figures 4A-B , Supplementary Figure S4 ).
The ability of miR-194 to enhance NE transdifferentiation was further tested using a locked nucleic acid (LNA) inhibitor that specifically inhibits the activity of this oncogenic miRNA. In these experiments, we exploited the fact that the LNCaP model can be transdifferentiated from adenocarcinoma-like to NE-like cells by androgen deprivation (46) . As expected, growth of cells in charcoal-stripped serum (CSS) resulted in upregulation of NE markers ENO2 (encoding neuron-Specific Enolase) and SYP (encoding synaptophysin) and increased the length of neurite-like extensions ( Figures 4C-D) . Importantly, the miR-194 LNA inhibitor effectively blocked this transdifferentiation ( Figures 4C-D) . Collectively, these data reveal that miR-194 can drive the acquisition of NE features, which corresponds with its increased activity in clinical NEPC.
FOXA1, an inhibitor of neuroendocrine transdifferentiation, is targeted by miR-194
To understand at a mechanistic level how miR-194 promotes PCa transdifferentiation, we searched the targetome for genes with a known role in PCa progression. Of particular interest was FOXA1, a transcription factor with a critical role in maintaining epithelial lineage in the prostate (47) . Consistent with this function, a recent report demonstrated that loss of FOXA1 leads to NE differentiation in prostate cancer (48) . Multiple miR-194 Ago-HITS-CLIP peaks were found within the FOXA1 3'UTR, one of which contains a perfect 7-mer seed match ( Figure 5A ). We confirmed that miR-194 decreases the levels of FOXA1 mRNA and FOXA1 protein in the LNCaP and 22Rv1 models ( Figures 5B-C) .
Importantly, the activity of FOXA1 and miR-194 is inversely correlated in clinical PCa (NEPC and primary PCa; Figure 5D ). Collectively, these findings reveal a functional interaction between miR-194 and FOXA1.
A recently described mechanism by which FOXA1 suppresses NE differentiation is by directly repressing the IL8 gene, a chemokine elevated in NEPC, which results in dampening of the MAPK/ERK pathway, a known driver of NEPC (48, 49) . Supporting the relevance of this mechanism in miR-194's mode of action, transfection of prostate cancer cells (LNCaP and 22Rv1) with miR-194 caused upregulation of IL8 ( Figure 5E ). Moreover, miR-194 also enhanced MAPK/ERK pathway activity ( Figure 5F ), and miR-194 activity was positively correlated with MAPK/ERK gene signatures in clinical NEPC ( Figure 5G and Supplementary Figure S5 ). Collectively, these data reveal that miR-194 promotes the emergence of NEPC at least in part by targeting FOXA1, which leads to upregulation of IL8 and enhanced MAPK/ERK pathway activity.
Targeting miR-194 suppresses the growth of prostate cancer with neuroendocrine features
Although miR-194 mediates the acquisition of an NE-like phenotype in prostate cancer, whether it represented a therapeutic target in this disease context is unclear. To investigate this possibility, we measured the growth of PCa cells treated with the miR-194 LNA inhibitor. Interestingly, the growth of all 4 cell line models tested could be suppressed by the inhibitor, but the models with NE features (PC3 and LNCaP-MR42D) were more sensitive than those with a more typical adenocarcinoma phenotype (LNCaP, LNCaP-MR49F) ( Figure 6A ). The miR-194 inhibitor was cytotoxic as revealed by cell viability assays ( Figure 6B ) and by counting dead cells ( Figure 6C ).
To examine the potential of targeting miR-194 in a more clinically-relevant setting, we turned to patient-derived CRPC organoids recently described by our team (33) . Models 201.1 and 201.2 were derived from dura and lung metastases, respectively, from a patient who died after receiving second-generation AR-targeted therapies (Enzalutamide, Abiraterone) and chemotherapies (Docetaxel, Cabazitaxel) (33) . 201.1 is a model of PSA-positive adenocarcinoma that expresses a mutated form of the AR (C687Y and T878A) that mediates resistance to Enzalutamide. In contrast, 201.2 has no AR or PSA expression but exhibits high expression of a neuroendocrine gene signature, focal staining of CD56, and concurrent genomic loss of TP53, PTEN and RB1 (33) . Representative IHC images of the expression of various markers in each model are shown in Figure 6D . As expected, miR-194 levels were higher in 201.2 compared to 201.1 ( Figure 6E ). The effect of the miR-194 LNA inhibitor on the growth of these 2 patient-derived models was evaluated by measuring organoid forming efficiency (OFE) and cell viability. Both models exhibited reduced OFE and cell viability in response to transfection with the inhibitor (Figures 6F-G) . However, similarly to the cell lines, the ARnull, NEPC-like 201.2 model was more sensitive to miR-194 inhibition than the adenocarcinoma-like 201.1 model ( Figures 6F-G) . Collectively, these findings -in both traditional cell lines and contemporary patient-derived models -provide evidence that targeting miR-194 has potential as a novel therapy for prostate cancer with NE features. Our study suggests that miR-194 is elevated in NEPC via 2 key mechanisms. First, by evaluating PCa cells treated with androgens and anti-androgens, we found that miR-194 is negatively regulated by the AR signalling axis. Interrogation of published cistromic data revealed no evidence for association of AR with regulatory elements proximal to MIR194 genes (data not shown); thus, we do not believe that the inverse relationship between AR and miR-194 represents a direct mode of transcriptional repression. Rather, we hypothesise that AR indirectly inhibits miR-194 expression through a mechanism that is yet to be elucidated. One possibility is that the transcription factor GATA2 serves as an intermediary: expression of GATA2 is known to be down-regulated by AR (54), and we previously demonstrated that GATA2 enhances the levels of miR-194 (32) . Future studies should investigate the role of this putative pathway in NEPC, particularly since GATA2 has been identified as a mediator of PCa metastasis and drug resistance previously (55) . Second, we found that gain or amplification of genomic regions encompassing the MIR194 genes is another mechanism that can result in elevated expression of miR-194 in aggressive forms of prostate cancer, including NEPC. MiR-194 is unusual in that it is encoded by 2 genes (MIR194-1 and MIR194-2) , and the observation that both are frequently gained further supports the relevance of this miRNA in disease progression.
DISCUSSION
Using an integrative approach that exploited cutting-edge biochemical (Ago-HITS-CLIP), molecular (RNA-seq) and bioinformatics (EISA) techniques, we identified ~160 genes that miR-194 putatively targets in PCa. Of note, gene signatures enriched in this targetome include those involved in cell movement, cytoskeletal organisation (including axon guidance) and focal adhesion. We propose that dysregulation of these networks by elevated miR-194 during PCa progression EMT (32) and transdifferentiation from an adenocarcinoma-like cell to an NE-like cell (this study). While this hypothesis remains to be proven, we note the EMT and emergence of NE features are manifestations of cell plasticity that share many fundamental characteristics; indeed, it appears as if the re-activation of a developmental EMT program is a crucial strategy by which PCa cells evolve towards a NE lineage (1, 56) .
In addition to a miR-194 targetome enriched for cell movement, structure and attachment, we identified FOXA1 as a key target gene via which miR-194 influences the emergence of NEPC.
Supporting our findings, FOXA1 has been previously identified as a target of miR-194 in non-small cell lung cancer (NSCLC); interestingly, in this context it appeared to act as a tumour suppressor, with upregulation of miR-194 suppressing tumour proliferation, invasion and metastasis (57) . The reported), while a miR-155 antagomiR is in phase I trials for lymphoma (63) . The attraction of targeting miRNAs in cancer comes from the potential to concurrently modulate multiple pathways involved in tumour growth and progression. In the case of miR-194, an inhibitor could stabilise multiple plasticity suppressing factors (e.g. FOXA1) and tumour suppressors (e.g. SOCS2 (32)), leading to inhibition of multiple plasticity-and metastasis-promoting pathways (e.g. MAPK/ERK, IL8 and STAT3). We aim to undertake further pre-clinical evaluation of a miR-194-targeted therapy to treat NEPC and/or re-sensitise NEPC tumours to AR-targeted therapies.
In addition to its potential as a therapeutic target, it is worth noting that miR-194 was first linked to PCa as a serum marker of poor prognosis in a patients with localised disease (45) . In this earlier disease context, high levels of serum miR-194 likely demarcates tumours with increased plasticity and hence a propensity to metastasize. However, whether miR-194 is a marker of advanced PCa and CPRC is unknown. Given the strong inverse correlation between miR-194 and AR activity, it is tempting to speculate that circulating miR-194 could be used to identify CRPC patients with ARindependent tumours (e.g. NEPC) and therefore guide therapy, but this concept remains to be tested in patient cohorts.
In summary, our study demonstrates that miR-194 can promote adenocarcinoma-NE transdifferentiation and the growth of NEPC by targeting a network of genes including the lineagedefining transcription factor FoxA1. These findings deliver new molecular insights into lineage plasticity in PCa, and provide impetus to further investigate the potential of targeting miR-194 as a novel therapy for NEPC.
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Ago-HITS-CLIP and RNA-seq data have been deposited with the Gene Expression Omnibus bank under accession number GSE137072. (42)). For each target identified, the Pearson correlation coefficient and its q value was calculated and plotted as −log q (on y-axis) versus correlation coefficient (on x-axis). To indicate the bias towards negative correlations, the mean correlation coefficient is indicated by a vertical black line and the 25th and 75th percentiles are coloured red and blue, respectively. P value was determined using a one-sided t test (****, p < 0.0001). 
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